Arjun Goyal Buys 44,939 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Arjun Goyal purchased 44,939 shares of the stock in a transaction on Thursday, May 15th. The shares were purchased at an average price of $12.24 per share, with a total value of $550,053.36. Following the acquisition, the director now owns 44,939 shares in the company, valued at approximately $550,053.36. The trade was a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Arjun Goyal also recently made the following trade(s):

• On Friday, May 16th, Arjun Goyal purchased 417,646 shares of Centessa Pharmaceuticals stock. The shares were purchased at an average price of $12.73 per share, with a total value of $5,316,633.58.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $13.20 on Wednesday. The company has a fifty day simple moving average of $13.31 and a 200 day simple moving average of $15.54. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.76 billion, a P/E ratio of -8.63 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. Sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on CNTA shares. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a “buy” rating and a $30.00 price objective for the company. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of CNTA. JPMorgan Chase & Co. grew its position in Centessa Pharmaceuticals by 1,969.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock valued at $2,173,000 after purchasing an additional 129,335 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after purchasing an additional 5,316 shares during the period. Wellington Management Group LLP grew its position in Centessa Pharmaceuticals by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock valued at $1,928,000 after purchasing an additional 14,494 shares during the period. Franklin Resources Inc. boosted its holdings in Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after acquiring an additional 660 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.